All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @summermcdermaid on TikTok · 55s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @summermcdermaid's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I just got all of my peptides in the mail, so I'm going to go over everything I got and
  2. 0:03why I'm taking them.
  3. 0:05First things first, this is not medical advice.
  4. 0:07I am not a doctor.
  5. 0:08I'm not recommending anything.
  6. 0:10I'm just simply sharing my journey with peptides.
  7. 0:14First is GHK-Cu.
  8. 0:15I am so excited for this.
  9. 0:16I'm taking this for skin and hair health.
  10. 0:19This one might be a little controversial, but I'm doing a low dose of tricevatide just
  11. 0:23once a week for inflammation purposes.
  12. 0:25NAD for focus, mental clarity, recovery, and overall wellness.
  13. 0:30MOTS-c for metabolic function, energy, and fat utilization.
  14. 0:35This is great to take alongside a GLV.
  15. 0:38Last is Sarah Morlin.
  16. 0:39I'm taking this mostly for lean muscle support and overall body composition, but this helps
  17. 0:45with sleep and recovery.
  18. 0:46And that's it.
  19. 0:47That's all I'm taking for my first time stacking peptides.
  20. 0:49And I'm really excited.
  21. 0:50Are you posting a lot more about my peptide journey so follow if you're interested?

@summermcdermaid's peptide therapy claims, fact-checked

summermakayla

TikTok creator

15.8K viewsWatch on TikTok

Quick answer

The creator describes a self-directed stack of five compounds obtained via a physician referral on social media, including tirzepatide, which is an FDA-regulated drug with specific approved indications that do not include general inflammation management. Several other compounds in the stack, including MOTS-c and sarmorelin, lack adequate human clinical trial data to support the specific benefits claimed. Combining growth hormone-related peptides with a GIP/GLP-1 agonist and mitochondrial peptides simultaneously raises interaction and monitoring questions that are not addressed in the video.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @summermcdermaid's peptide therapy claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@summermcdermaid's peptide therapy claims, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@summermcdermaid's peptide therapy claims, fact-checked" from summermakayla. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator describes a self-directed stack of five compounds obtained via a physician referral on social media, including tirzepatide, which is an FDA-regulated drug with specific approved indications that do not include general inflammation management.

The reason this review is not generic is the source wording and the canonical claim label "peptides if i m pronouncing any of these wrong it s because i am not." In this clip, the useful excerpt is: "I just got all of my peptides in the mail, so I'm going to go over everything I got and why I'm taking them." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

GHK-Cu has the strongest supporting evidence of any compound in this stack, primarily from topical dermatology research, but systemic injection data in humans remains limited.
People who land here are usually comparing the Peptide social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator describes a self-directed stack of five compounds obtained via a physician referral on social media, including tirzepatide, which is an FDA-regulated drug with specific approved indications that do not include general inflammation management.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator describes a self-directed stack of five compounds obtained via a physician referral on social media, including tirzepatide, which is an FDA-regulated drug with specific approved indications that do not include general inflammation management. Several other compounds in the stack, including MOTS-c and sarmorelin, lack adequate human clinical trial data to support the specific benefits claimed. Combining growth hormone-related peptides with a GIP/GLP-1 agonist and mitochondrial peptides simultaneously raises interaction and monitoring questions that are not addressed in the video.
  • The FDA issued a specific safety communication in 2024 warning about compounded tirzepatide obtained outside licensed pharmacy channels, making its casual inclusion in a social media haul video a significant red flag.
  • GHK-Cu has the strongest supporting evidence of any compound in this stack, primarily from topical dermatology research, but systemic injection data in humans remains limited.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • The FDA issued a specific safety communication in 2024 warning about compounded tirzepatide obtained outside licensed pharmacy channels, making its casual inclusion in a social media haul video a significant red flag.
  • GHK-Cu has the strongest supporting evidence of any compound in this stack, primarily from topical dermatology research, but systemic injection data in humans remains limited.
  • MOTS-c human trials are essentially nonexistent. The Lee et al. (2015, Cell Metabolism) study that generated excitement was conducted in mice and cell models, not humans.
  • Starting five compounds simultaneously makes it impossible to attribute any effect, positive or negative, to a specific compound. This is a basic problem with any multi-compound self-experiment.
  • NAD precursor supplementation has the most replicated human data of any compound in this category, but direct focus and mental clarity benefits are not what the published trials primarily measured.
  • Tirzepatide is a dual GIP/GLP-1 receptor agonist approved for metabolic disease. It is not categorized as a traditional peptide in the same class as BPC-157 or GHK-Cu and should not be treated as a low-stakes wellness supplement.
  • Sarmorelin stimulates growth hormone release, which means it carries the same contraindication considerations as growth hormone therapy itself, including active malignancy risk, a fact absent from the creator's summary.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @summermcdermaid actually say?

In a casual unboxing video, the creator walked through five compounds she received in the mail: GHK-Cu for skin and hair, what she called "tricevatide" (almost certainly tirzepatide) at a low weekly dose for inflammation, NAD for focus and recovery, MOTS-c for metabolic function and fat utilization, and "Sarah Morlin" (sarmorelin, a GHRH analogue) for lean muscle, sleep, and recovery. She acknowledged she is not a doctor and framed the whole thing as a personal journey, not medical advice.

To her credit, that disclaimer is more than most creators bother with. But disclaimers do not make ambiguous or incomplete claims disappear. Several of the stated reasons for taking these compounds range from loosely supported to genuinely contested, and one compound in the stack is not technically a peptide at all in the way most viewers would understand the term.

Does the science back this up?

It depends heavily on which compound you are asking about. GHK-Cu has the most legitimate topical skin data. NAD precursors have real but often overstated human evidence. The others are in far murkier territory.

GHK-Cu (copper peptide) has a reasonable body of in-vitro and some clinical evidence for collagen stimulation and wound healing. A review by Pickart and Margolina (2018, Cosmetics) found consistent signaling effects, though most strong data is topical, not systemic. NAD supplementation via precursors has been studied in humans, but direct NAD injections or infusions for "focus and mental clarity" as a primary benefit lack strong clinical trial support. Most human NAD data focuses on metabolic and cardiovascular markers (Martens et al., 2018, Cell Metabolism). MOTS-c is a mitochondrial peptide with genuinely interesting early research in metabolic function (Lee et al., 2015, Cell Metabolism), but human clinical trials are essentially nonexistent. Calling it proven for "fat utilization" in humans is a stretch. Sarmorelin's evidence for lean body composition in healthy adults is limited, mostly extrapolated from growth hormone deficiency studies.

What did they get wrong (or right)?

The tirzepatide claim is the most significant problem here. Tirzepatide is a GIP/GLP-1 receptor agonist approved by the FDA for type 2 diabetes and obesity. Taking it "for inflammation purposes" at a "low dose" is not a recognized clinical indication.

There is some early mechanistic interest in GLP-1 receptor agonists and inflammatory pathways, but using an approved drug off-label at self-directed doses for a vague anti-inflammatory goal is not the same thing as established evidence. Tirzepatide is also not a peptide in the traditional "peptide therapy" sense that the hashtag community typically uses. It is a synthetic dual-receptor agonist, and the FDA has specifically flagged compounded tirzepatide as a significant patient safety concern (FDA, 2024). Bundling it into a casual TikTok haul without addressing that context is genuinely misleading regardless of the disclaimer. The GHK-Cu claim for skin and hair is the most defensible thing in this video. The NAD claims for "overall wellness" are vague enough to be nearly unfalsifiable. MOTS-c for energy is plausible but not proven in humans.

What should you actually know?

A few things matter before anyone watches a video like this and considers copying it. First, stacking multiple compounds with different mechanisms of action simultaneously makes it nearly impossible to know what is doing what, or what is causing any side effect. Starting five compounds at once is poor experimental design even by self-experimentation standards.

Second, the FDA has issued specific guidance warning consumers about compounded tirzepatide and semaglutide products obtained outside of traditional pharmacy channels. Receiving any of these in the mail from a social media referral chain warrants serious scrutiny of the prescribing and dispensing process. Third, MOTS-c and sarmorelin have so little human safety data that framing them as obvious additions to a starter stack understates real unknowns. Fourth, none of these compounds should be evaluated purely on the basis of a TikTok haul video, including this one. If you are curious about peptide therapy, the appropriate conversation starts with a licensed clinician who can review your bloodwork and medical history, not a creator's mail delivery.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

summermakayla · TikTok creator

15.8K views on this video

If I’m pronouncing any of these wrong it’s because I am NOT a doctor and this is not medical advice, just my journey!🤍 I get mine from @Dr. Shuayto & you can too! #peptide

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the fda?

The FDA issued a specific safety communication in 2024 warning about compounded tirzepatide obtained outside licensed pharmacy channels, making its casual inclusion in a social media haul video a significant red flag.

What does the video say about ghk-cu has the strongest supporting evidence of any compound in?

GHK-Cu has the strongest supporting evidence of any compound in this stack, primarily from topical dermatology research, but systemic injection data in humans remains limited.

What does the video say about mots-c human trials?

MOTS-c human trials are essentially nonexistent. The Lee et al. (2015, Cell Metabolism) study that generated excitement was conducted in mice and cell models, not humans.

What does the video say about starting five compounds simultaneously makes it impossible to attribute any?

Starting five compounds simultaneously makes it impossible to attribute any effect, positive or negative, to a specific compound. This is a basic problem with any multi-compound self-experiment.

What does the video say about nad precursor supplementation has the most replicated human data of?

NAD precursor supplementation has the most replicated human data of any compound in this category, but direct focus and mental clarity benefits are not what the published trials primarily measured.

What does the video say about tirzepatide?

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved for metabolic disease. It is not categorized as a traditional peptide in the same class as BPC-157 or GHK-Cu and should not be treated as a low-stakes wellness supplement.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by summermakayla, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.